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ABSTRACT
Lung cancer is the leading cause of tumor-related death worldwide and more 
efforts are needed to elucidate lung carcinogenesis. Here we investigated the 
expression of 641 miRNAs in lung tumorigenesis in a K-Ras(+/LSLG12Vgeo);RERTn(ert/ert) mouse 
model and 113 human tumors. The conserved miRNA cluster on chromosome 12qF1 
was significantly and progressively upregulated during murine lung carcinogenesis. 
In particular, miR-494-3p expression was correlated with lung cancer progression 
in mice and with worse survival in lung cancer patients. Mechanistically, ectopic 
expression of miR-494-3p in A549 lung cancer cells boosted the tumor-initiating 
population, enhanced cancer cell motility, and increased the expression of stem cell-
related genes. Importantly, miR-494-3p improved the ability of A549 cells to grow 
and metastasize in vivo, modulating NOTCH1 and PTEN/PI3K/AKT signaling. 
Overall, these data identify miR-494-3p as a key factor in lung cancer onset and 
progression and possible therapeutic target.
INTRODUCTION
Despite an improved understanding of lung 
carcinogenesis, lung cancer is still a major cause of cancer-
related death worldwide with increasing incidence in non-
smoker subjects. Non Small Cell Lung Cancers (NSCLCs) 
comprise the majority of cases and genetic aberrations in 
cancer nodal genes, such as TP53, kRAS, EGFR, and ALK 
among others, have been recently described. Although 
much effort is focused in early disease detection through 
the introduction of novel biomarkers, the prognosis 
of NSCLC patients is poor and the rate of recurrence 
is unacceptably high [1]. Genetic models of disease 
represent a valuable tool to gain insights into molecular 
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aberrations that underpin tumor onset and progression [2]. 
Genetically engineered mouse models may also uncover 
pre-neoplastic precursor lesions, which are often absent 
in human samples. Therefore, in this investigation, we 
studied the conditional knock-in K-Ras(+/LSLG12Vgeo);RERTn(ert/
ert) mouse model of lung cancer [3] and systematically 
profiled microRNA (miRNA) contents from histologically 
defined normal, hyperplastic, adenomatous and tumor lung 
specimens. In this model, lung carcinogenesis is driven 
by oncogenic K-RasG12V induction by 4-hydroxitamoxifen 
(4-OHT) administration [4]. Lung adenocarcinoma arises 
with complete penetrance, evolving from normal to 
hyperplasia, adenoma and finally cancer [3, 5].
Different studies highlighted miRNAs involvement 
in human tumors, including NSCLCs [6], and implicated 
their roles as oncogenes [7] or tumor suppressors 
[2, 8] through post-transcriptional modulation of 
gene expression. Several molecular and epigenetic 
mechanisms are involved in miRNAs deregulation in 
cancer, mostly because miRNAs are often localized 
at fragile sites [9], cancer susceptibility loci [9] or in 
proximity of CpG islands [10]. Despite numerous studies 
on miRNA deregulation in lung cancer, a consensus on 
which miRNAs are crucial for lung carcinogenesis and 
progression has remained elusive.
In this study, we aimed to identify mechanisms 
of disease conserved between experimental models 
of disease and NSCLC patients to eventually provide 
novel theranostics for early lung cancer diagnosis and, 
potentially, for novel therapeutic strategies.
RESULTS
Chromosome 12qF1 miRNAs expression is 
increased during lung tumorigenesis
We profiled 641 miRNAs in laser-assisted 
microdissected samples from normal Tamoxifen non-
induced (N), or Tamoxifen induced non-neoplastic 
(4-OHT+ N) lung parenchyma and neoplastic tissues 
(Hyperplasia, Hyp, Adenoma, Ad and Adenocarcinoma, 
AdCa) isolated from K-Ras(+/LSLG12Vgeo);RERTn(ert/ert) mice, 
a well-established model of lung cancer tumorigenesis 
(Figure 1A; [3]). This analysis showed extensive 
miRNAs deregulation during lung cancer development 
(Supplementary Tables 1-6 and Supplementary Figure 1A). 
In particular, non-neoplastic tissues exhibited a distinctive 
miRNAs expression profiling compared to pre-neoplastic 
and cancerous lesions (Figure 1B). Interestingly, most of 
the miRNAs belonging to the murine chromosome 12qF1 
cluster (30 out of 54 miRNAs, 55%) were overexpressed 
during oncogenic lung transformation (Figure 1C). Single 
qPCR analyses confirmed the upregulation of chromosome 
12qF1 miRNAs (Supplementary Figure 1B).
Since 12qF1 miRNAs expression has been 
correlated with mice aging [11, 12], we next analyzed 
miRNAs levels in non-neoplastic lung tissues from 
K-Ras(+/LSLG12Vgeo);RERTn(ert/ert) mice at different ages. Our 
data show that 12qF1 miRNAs were not affected by lung 
aging, as 26 miRNAs (48%) were not expressed in all 
samples and 15 miRNAs (28%) exhibited comparable 
levels in all specimens. Indeed, only nine (17%) and 4 
(7%) miRNAs were decreased or overexpressed (2.5-folds 
difference), respectively, in older tissues (Supplementary 
Figure 1C). Therefore, the 12qF1 miRNAs upregulation 
in lung tissues from the K-Ras(+/LSLG12Vgeo);RERTn(ert/ert) mouse 
model is correlated with lung carcinogenesis.
The 14q32 miR-494-3p is correlated to lung 
cancer patients’ prognosis
12qF1 murine miRNAs region is conserved in 
the human genome and maps to the DLK1-DIO3 locus 
on chromosome 14q32. We therefore analyzed a subset 
(n = 10) of those miRNAs (miR-127, -300, 370, -379, 
-382, -409-3p, -412, -431, -494-3p and -543) in a series 
of 57 NSCLC patients. Although these miRNAs were 
not generally significantly overexpressed in lung cancer 
compared to normal tissues (Supplementary Figure 2A), 
patients with high levels of miR-494-3p had a shorter 
disease-free survival time (p = 0.046; Supplementary 
Figure 2B). To further substantiate these findings, we next 
examined a larger cohort of 113 NSCLC patients. High 
miR-494-3p levels were significantly associated with 
shorter patients’ overall survival (p = 0.03; Figure 2A). 
No other miRNA individually correlated with NSCLC 
patients’ survival. However, the elevated presence of 
the majority of 14q32 miRNAs (9 out of 10 miRNAs) in 
tumor tissues was associated with shortened disease-free 
survival (p = 0.01; Figure 2B). 
Chromosome 14q32 miRNAs expression has 
been previously associated with a stem-like subtype in 
hepatocellular carcinoma [13]. Accordingly, we next 
looked at a potential relationship between 14q32 miRNAs 
expression and cancer stem cell markers, and we examined 
the expression of CD44, ABCG2, ALDH1A1, NANOG 
and c-MYC genes in 53 tumor samples (Figure 2C and 
Supplemental Figure 2C). ABCG2 was increased in tumors 
with concurrent chromosome 14q32 miRNAs upregulation 
(Figure 2C). Moreover, ROC analyses demonstrated that 
ABCG2 levels accurately discriminated NSCLC patients 
with high- or low-miRNAs expressors (Figure 2D; p = 
0.03).
To begin to test a role of this association in disease 
dissemination [14], we next examined the expression 
of 14q32 miRNAs in 16 cases of NSCLC where tumor 
bulk and the tumor invasive front were isolated by laser-
assisted microdissection. miR-494-3p expression was 
significantly higher in the invasive front than in tumor 
bulk specimens (p = 0.03; Figure 2E). The expression 
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Figure 1: Overexpression of chr.12qF1 miRNAs during lung carcinogenesis in the K-Ras(+/LSLG12Vgeo);RERTn(ert/ert) mouse 
model. A. Representative images of mice lung tumorigenesis: normal lung tissue (N) without Tamoxifen administration; non-neoplastic 
lung tissue after Tamoxifen administration (4-OHT+ N); hyperplasia (Hyp); lung adenoma (Ad); lung adenocarcinoma (AdCa). Scale 
bar 100 µm or 50 µm (insets). B. Unsupervised hierarchical clustering of microdissected murine tissues profiled for miRNAs contents. 
C. Schematic representation of chr.12qF1 miRNAs and their expression levels during murine lung cancer progression. miRNAs Relative 
Quantities (RQ) were calculated over normal samples, without K-Rasv12 oncogene induction by 4-OHT administration. Grey spot: RQ ≤ 
0.2; Pink spot:5≤RQ≤50; Red spot: RQ≥50; Black spot: no expression variation; − : miRNA not present within the TaqMan Low Density 
Array. 
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of other miRNAs was indistinguishable between the two 
tumor areas (Supplementary Figure 2D). 
Together, the results obtained with the murine lung 
cancer model and analysis of patient cohorts suggested 
that miR-494-3p and, to a lesser extent, chromosome 14 
miRNA cluster correlated with a more invasive, ABCG2-
positive phenotype in NSCLC. 
Regulation of miR-494-3p expression
The 14q32 locus undergoes imprinting [15], and we 
next further characterized how miR-494-3p expression is 
regulated in human lung tissues. Firstly, we demonstrated 
in our series of 57 NSCLCs that there is a direct 
correlation between the precursor pri-miR-494 levels and 
its mature miR-494-3p expression (p = 0.002; Figure 3A). 
In addition, tumors with high pri-miR-494 expression 
showed higher miR-494-3p levels (p = 0.02; Figure 3B).
We next looked at the epigenetic status of the 16 
CpG sites at the intergenic differentially methylated 
(IG-DMR) region, which contributes to the imprinting 
of the DLK1-DIO3 locus [15], in a subset of matched 
normal lung and cancer tissues. Normal tissues showed 
a significant higher IG-DMR CpG methylation levels 
(mean: 60.9%) than tumor (mean: 40%) counterparts (n 
= 12; Figure 3C, 3D; p = 0.0005). In addition, IG-DMR 
demethylation in tumors relative to non-neoplastic lung 
parenchyma was more evident in NSCLCs with elevated 
pri-miR-494 levels (Figure 3E). Finally, we examined 
submicroscopic genomic alterations at the q11.2-q32.33 
region of chromosome 14 by a-CGH in subsets of lung 
tissues and paired non-neoplastic counterparts (n = 20). 
This analysis showed that the 14q region was marginally 
affected by genomic rearrangements, since it was gained 
in 4 samples (20%), lost in one specimen (5%), and 
unchanged in 15 samples (75%) (Supplementary Table 
7). Despite sample 17 showed a gain at q32.32-q32.33 
band, this region does not include the DLK1-DIO3 locus 
(q32.2-q32.31). Further, there was no direct correlation 
between 14q genomic status and pri-miR-494 expression 
(Figure 3F). These data show that epigenetic but not 
genetic alterations could contribute to miR-494-3p 
deregulation in lung cancer, prompting us to investigate 
potential miR-494-3p-directed signaling pathways in 
NSCLC.
Figure 2: Chromosome 14q32 miRNAs and NSCLC progression in humans. A. Kaplan-Meier curves of NSCLC patients 
overall survival according to miR-494-3p levels. p = 0.03 by Log-Rank test. B. Kaplan-Meier curve of NSCLC patients’ disease-free 
survival according to expression of chr.14q32 miRNAs. p = 0.01 by Log-Rank test. HR, Hazard Ratio; CI, Confident Interval. C. ABCG2 
gene expression was analyzed in NSCLC tissues of patients with (>8) or without (≤8) major upregulation of 14q32 miRNAs.*, p = 0.04 by 
unpaired t test. D. ROC analysis was performed to identify the ability of ABCG2 to discriminate between high and low chr.14q32 miRNAs 
expressors (p = 0.03). E. miR-494-3p analysis in tumor bulk and invasive front of 16 NSCLC cases. *, p = 0.03 by paired t test.
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miR-494-3p regulates pathways involved in 
cancer and development
For these studies, we first analyzed the expression 
of 36 genes implicated in key cancer pathways 
(Supplementary Table 8) after modulation of miR-494-
3p expression in A549 cells (Supplementary Figure 3A). 
Interestingly, forced expression of miR-494-3p did not 
affect apoptosis-related mechanisms (Figure 4A), but 
significantly increased the levels of PROM1, CDKN1A, 
NUMBL and KLF4, four stem cell-related mRNAs, 
compared to controls (p = 0.007, 0.003, 0.001 and 0.005, 
respectively; Figure 4B). Consistent with these findings 
[16], factors involved in epithelial-to-mesenchymal 
transition (EMT) were overexpressed after upregulation 
of miR-494-3p (Figure 4C). In particular, ZEB2 and S100A 
mRNAs were significantly increased upon miR-494-3p 
Figure 3: Regulation of miR-494-3p expression. A., B. Pri-miR-494 expression was investigated in 57 NSCLC samples and 
compared with miR-494-3p levels. A) miR-494-3p and pri-miR-494 expression correlation. Spearman’s rank correlation and coefficient 
rho along with 95% confidence intervals (CI) are shown (p = 0.002). Each point represents a sample. B) Pri-miR-494 expression levels 
compared with miR-494-3p levels. *, p = 0.02 by unpaired t test. Each point represents a sample. C., D. Methylation status of 16 CpG 
sites at the IG-DMR of human DLK1-DIO3 region was analyzed in 12 matched lung normal and NSCLC specimens as well as in a control 
sample (peripheral blood from healthy individual). Significant reduction of methylation was found in tumor samples compared to their 
normal counterpart. ***, p = 0.0005 by Mann-Whitney U test. E. The IG-DMR decreased methylation of NSCLC samples (n = 12) was 
analyzed in function of pri-miR-494 expression levels. F. Chromosome 14q genomic alterations were analyzed by a-CGH in 20 tumor 
samples. Individual pri-miR-494 levels are displayed in NSCLCs according to the genomic alteration found. Bar, individual sample.
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overexpression (p = 0.03 and 0.003, respectively; Figure 
4C). Ingenuity pathway analysis suggested that miR-494-
3p modulation influenced cellular networks implicated 
in “cell death and survival, embryonic development and 
organism development” (Score 45; focus molecules: 18; 
Figure 4D). Based on these findings, we next looked at 
a potential role of miR-494-3p in potentially modulating 
lung cancer “stemness”.
miR-494-3p is involved in lung tumor-initiating 
population maintenance
To better understand a potential involvement of 
14q32 miRNAs and, in particular, miR-494-3p in tumor-
initiating progenitor maintenance, the side (SP) and non-
side (NSP) cell populations were sorted from A549 lung 
cancer cells (Figure 5A). Eight out of the ten analyzed 
Figure 4: miR-494-3p involvement in molecular pathways relevant for cancer progression. A.-C. Heat-Maps of genes 
involved in apoptosis (A), cancer stem cells maintenance (B; PROM1, p = 0.007; NUMBL, p = 0.001; KLF4, p = 0.005; CDKN1A, p = 
0.003, by Mann-Whitney U test), or epithelial-to-mesenchymal transition (C; ZEB2, p = 0.03; S100A, p = 0.003, by Mann-Whitney U test) 
upon enforced expression of a control (Ctrl) or miR-494-3p Mimic in A549 cultures. One experiment representative of four is shown. Red 
and blue colors indicate over or underexpression of the gene in miR-494-3p-expressing cells, respectively. D. Ingenuity pathway analysis 
of the 36 analyzed genes in A549 cells with ectopic miR-494-3p or control construct expression returned a signaling network with impact 
on cell survival, embryonic and organism development (Score 45). Genes found to be overexpressed or downmodulated in A549 cells 
transfected with the miR-494-3p compared to the control are shown respectively in red and green. 
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Figure 5: miR-494-3p contributes in cancer progenitor cells maintenance and tumor growth in vivo. A. The side 
population (SP) analysis was performed in A549 cultures and the SP and nonSP (NSP) were isolated as the population that disappears after 
Verapamil incubation (+Vera) by FACS sorting. The SP percentage is shown. B. Chromosome 14q32 miRNAs expression was investigated 
in SP and NSP components. The heatmap shows miRNAs expression levels in the two populations. Red and blue colors indicate high 
or low expression, respectively. C. miR-494-3p expression in A549-SP and -NSP populations (fold difference = 8.2). Bars represent the 
average miR-494-3p expression level (RQ) from three independent experiments. D., E. A549 cells were transfected with a miR-494-3p or 
a control (Ctrl) Mimic and the SP was analyzed by FACS as in A. The percentage of the SP is shown within each graph and quantified from 
four independent experiments in E. *, p = 0.02 by Mann-Whitney U test. F., G. A549 cells with forced miR-494-3p or a control Mimic 
expression were plated in low-adhesion plates in serum-free media. The ability of A549 cells to form spheres was investigated after 7 days 
when the number (F) and size (G) of A549-spheres were analyzed (*, p = 0.04 for both analyses, by Mann-Whitney U test). Representative 
images of A549-sphere are shown (G). Scale bars indicate 25 µm. Bars represent the average from three independent experiments. H., I. 
A549 cultures transfected with a miR-494-3p or a control (Ctrl) Mimic were subcutaneously injected in the right flank of athymic nude 
mice (n = 7 per condition). Tumor growth was monitored with a caliper for 18 days, after which mice were sacrificed and tumors were 
harvested (H). Tumor growth (I) was calculated using the formula: Volume = (width)2 × length/2. ***, p = 0.006 by Mann-Whitney U test.
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14q32 miRNAs were expressed by A549 cells at baseline 
conditions (namely miR-127,-379, -382, -409-3p, -412, 
-431, -494-3p and -543; Supplementary Figure 3B). 
Importantly, SP cells exhibited a distinctive miRNAs 
expression profile compared to NSP cells (Figure 5B), as 
miR-494-3p miRNA was the most overexpressed miRNA 
in the SP fraction (FC = 8.2; Figure 5C). 
Next, we overexpressed miR-494-3p in A549 
and examined the percentage of SP cells compartment 
by FACS. Higher levels of miR-494-3p resulted in a 
significant increase of SP, compared to controls (p = 0.02; 
Figure 5D-5E). Conversely, reduction of miR-494-3p 
levels in A549 by transfection with a miRNA Inhibitor (p 
= 0.03; Supplementary Figure 3C) did not affect the SP 
compartment compared to control (Supplementary Figure 
3D). Ectopic miR-494-3p expression in non-adherent 
culture condition significantly enhanced A549 sphere 
formation ability and size, a marker of stemness, compared 
to control incubations (p = 0.04 for both analyses; Figure 
5F, 5G). To further test a role of miR-494-3p in sustaining 
tumor growth in vivo, A549 cells overexpressing miR-
494-3p or control miRNA were injected subcutaneously in 
the lower flank of athymic mice (n = 14; Figure 5H). A549 
cells with forced overexpression of miR-494-3p generated 
larger tumors compared to control cultures 18 days after 
injection (p = 0.006; Figure 5I).
Figure 6: miR-494-3p enhanced lung cancer cells motility in vitro and in vivo. A. A549 cells were transfected with a miR-
494-3p or a control (Ctrl) Mimic. 48h from transfection (T0) a wound was made in the monolayer and cells were allowed to migrate for 
24h (T24). Representative images at T0 and T24 are shown (left). Scale bars, 100 µm. Right, quantification of the wound closure. Bars 
represent the average from three independent experiments, U, arbitrary units; **, p = 0.008 by unpaired Student’s t test. B.-E. A549 cultures 
transfected with a miR-494-3p or a control Mimic were intravenously injected into the lateral tail vein of athymic nude mice (n = 13 per 
condition; B). The onset of lung tumor metastasis was monitored using MRI (C) and mice were sacrificed after 18 days from the injection. 
At harvesting, lungs were FFPE (D) and the number and area of metastatic foci (red lines) were identified and scored on H&E sections 
(scale bars, 100 µm). A549 cells transfected with miR-494-3p generated significantly more and larger metastatic foci than controls (E). ***, 
p = 0.0002 and **, p = 0.002 by Mann-Whitney U test.
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miR-494-3p overexpression enhances tumor 
motility in vitro and in vivo
Based on the above results, we next analyzed the 
role of miR-494-3p in sustaining tumor cell motility and 
metastatic dissemination in vivo. In a wound-healing 
assay, overexpression of miR-494-3p enhanced A549 
cells migration compared to control samples (Ctrl) 72 
h after transfection (p = 0.008; Figure 6A). Moreover, 
we confirmed the ability of miR-494-3p to enhance 
cell migration by a Boyden chamber assay (p = 0.02; 
Supplementary Figure 4A and B). 
Then, A549 cells overexpressing miR-494-3p or 
a control miRNA (Ctrl) were injected in the lateral tail 
vein of athymic mice (n = 26, Figure 6B) and lung cancer 
foci formation was monitored by MRI at day 11 and 17 
after injection (Figure 6C). After harvesting mice lungs 
(day 18), metastatic foci were scored on histological 
sections (Figure 6D). Mice injected with A549-miR-494-
3p cells exhibited a significant increase in the number and 
surface area of metastatic foci compared to controls (p = 
0.0002 and p = 0.002, respectively; Figure 6E). No liver 
metastases were detected in mice (data not shown). 
miR-494-3p contribution to NOTCH1 pathway 
and PTEN regulation
Finally, we examined signaling pathways 
downstream of miR-494-3p potentially implicated in 
tumor-initiating cells. Analysis of a reporter array of 10 
oncogenic transcription factors (Supplementary Table 9, 
[17]), demonstrated that A549-miR-494-3p expressing 
cells exhibited significant increased NOTCH1 pathway 
activity (p = 0.04; Figure 7A). This was associated with 
significant upregulation of known NOTCH1 target genes, 
including CDKN1A and RBP-jk mRNAs (p = 0.003; 
Figure 7B). At the protein level, miR-494-3p upregulation 
increased both total NOTCH1 and NOTCH1 Intracellular 
Domain (NICD), as well as of CDKN1A (Figure 7C). 
Lastly, PTEN, a validated target of miR-494-3p [18, 19] 
and a NOTCH1-regulated protein [20], was significantly 
decreased in response to ectopic expression of miR-494-
3p (p = 0.04; Figure 7D). 
Based on these results of NOTCH1 activation and 
PTEN repression, we next looked at potential alterations 
of PI3K signaling in A549 cells with modulation of miR-
494-3p expression. Consistent with the data above, miR-
494-3p overexpression was associated with PI3K pathway 
activation, with increased levels of phosphorylated AKT 
at Ser473, AKT2 at Ser474, total and AKT-activated 
PDK1 (pPDK1T346), and phospo-S6RP protein (Figure 
7E). In contrast, reduced levels of miR-494-3p did not 
affect NOTCH1 activation (Supplementary Figure 4C 
and D), the levels of the NOTCH1 target CDKN1A 
(Supplementary Figure 4E), or of PI3K signaling in A549 
cells (Supplementary Figure 4F). 
Similar findings were observed in vivo, as 
xenografts and metastatic foci generated by miR-494-3p-
overexpressing A549 cells exhibited increased staining for 
phospo-S6RP (Figure 7F, 7G).
Therefore, our data provide comprehensive evidence 
that miR-494-3p promotes activation of PI3K signaling, 
with concomitant activation of AKT-mTOR-pS6RP in 
lung cancer, contributing to tumor cell proliferation. In 
parallel, miR-494-3p promotes NOTCH1 signaling and 
expression of downstream genes involved in EMT and 
cancer stemness (Figure 8). Together, these results point 
to a novel signaling axis orchestrated by miR-494-3p-
NOTCH1-PI3K activation (Figure 8) involved in lung 
cancer onset and metastatic dissemination. 
DISCUSSION
Several studies demonstrated the importance 
of miRNAs in the progression of different types of 
human tumors [6, 21]. Accordingly, miRNAs have 
been implicated in key hallmarks of cancer, dampening 
apoptosis, inducing cell proliferation, eliminating tumor 
suppressor pathways, and promoting angiogenesis, cell 
migration and invasion. For these properties, miRNAs 
have been proposed as diagnostic, prognostic and 
predictive biomarkers in cancer, and may provide novel 
therapeutic opportunities [21].
In this study, we showed that the overexpression 
of the murine chr.12qF1 miRNA cluster is involved in 
lung cancer development in a conditional knock-in mouse 
model of disease. This cluster is conserved in humans 
at chromosome 14q32, where its orthologue, the DIO3-
DLK1 miRNA cluster, is epigenetically deregulated in 
human lung cancer. More importantly, its overexpression 
or the upregulation of its member miR-494-3p, predicts a 
poorer prognosis in lung cancer patients.
In human lung tumors, miR-494-3p is highly 
expressed at the invasive front and its forced expression 
in lung cancer cells induces a stem-like phenotype, with 
increased side population compartment, tumor sphere 
formation, heightened cell motility, and increased 
NOTCH1 signaling. In turn, this promotes tumor 
growth and metastatic dissemination in vivo, potentially 
reflecting a general pro-tumorigenic role of miR-494-
3p by simultaneously downregulating the PTEN tumor-
suppressor and increasing NOTCH1 and PI3K-AKT-S6RP 
signaling in vitro and in vivo. 
Human chromosome 14q32 is an imprinted locus, 
which harbors both maternally (MEG3, MEG8 and 
asRTL1) and paternally expressed genes (DLK1, DIO3 
and RTL1). This region contains 54 paternally imprinted 
miRNAs that are organized in two segments and separated 
by a cluster of putative C/D box small nucleolar RNAs 
[13]. The overexpression of miRNAs associated with 
chromosome 12qF1 has been demonstrated in different 
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Figure 7: miR-494-3p contribution to NOTCH and PI3K/AKT pathways. A. Quantification of transcription factor (TF) 
activity in A549 transfected with miR-494-3p or control (Ctrl) Mimic. Bars represent the average from six independent experiments. *, 
p = 0.04 by Mann-Whitney U test. B. The gene expression levels (RQ) of NOTCH1 targets was investigated in A549 transfected as in A. 
CDKN1A expression was significantly upregulated after miR-494-3p overexpression compared with control. Bars represent the average 
from three independent experiments. **, p = 0.003 by Mann-Whitney U test. C.-D. NOTCH1 and miR-494-3p targets protein contents 
were analyzed in A549 cultures overexpressing or not (Ctrl) the miRNA. Numbers indicate the quantification of proteins in miR-494-3p 
overexpressing cells compared to control. *, p = 0.04 by Mann-Whitney U test. E. Western Blot analysis of PI3K/AKT pathway members 
after miR-494-3p overexpression. Numbers indicate the quantification of proteins and phospho-proteins (normalized on the corresponding 
total protein) in miR-494-3p overexpressing cells compared to control. F. Xenografts generated from A549 cultures transfected with miR-
494-3p or control (Ctrl) were analyzed for pospho-S6RP Ser235/236 by immunohistochemistry (pS6RP IHC). G. Immunostaining for 
phospho-S6RP Ser235/236 in A549-xenografts or in lung metastatic foci was scored multiplying the percentage of stained cells for the 
staining intensity. Tumors derived from A549 transfected with miR-494-3p Mimic showed higher pS6RP levels compared to controls. *, p 
= 0.01 by Mann-Whitney U test.
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genetically engineered mouse models of carcinogenesis, 
such as the c-Met hepatocellular carcinoma model [13] 
and K-RasLSL-G12D lung cancer model [22]. Importantly, in 
these previous studies a strong correlation between 12qF1 
miRNAs and cancer stem-cell features was observed [13, 
22]. In human lung tumors, DIO3-DLK1 miRNAs have 
been correlated with poorer survival [23, 24] and with a 
cell motility gene signature [23]. Specifically, miR-494 
has been shown to contribute to tumorigenesis of brain 
[25], lung [24] and liver [19] by affecting the PTEN/AKT 
pathway. 
Our data validate an important role of miR-494-3p 
and DIO3-DLK1 miRNAs cluster as important biomarkers 
of lung carcinogenesis, highlighting that upregulation of 
those miRNAs is an oncogenic mechanism conserved in 
humans, where epigenetic deregulation of DIO3-DLK1 
miRNAs is observed in more aggressive lung tumors. 
High levels of these miRNAs correlate with increased 
ABCG2 gene expression in lung tumor specimens, a 
bona fide marker of stem cells and of the side population 
compartment [26]. Accordingly, DIO3-DLK1 miRNAs 
were highly expressed in the side population, stem cell-
like compartment of lung cancer cells. Moreover, ectopic 
expression of the cluster member miR-494-3p enhanced 
the A549 side population compartment and CD133, 
NUMBL and KLF4 mRNA levels.
With respect to disease outcome, we have shown 
here that miR-494-3p predicts shorter survival of NSCLC 
patients, and mechanistically promotes increased tumor 
growth and metastatic dissemination via activation of 
a NOTCH1-PI3K-AKT axis, a key signaling network 
of lung carcinogenesis and important therapeutic target 
[27]. NOTCH1 signaling is an evolutionarily conserved 
pathway which plays an important role in cell-fate 
determination, cell proliferation and survival [28]. 
Perturbation of NOTCH1 signaling has been shown 
in different solid tumors such as lung [29], breast [30], 
liver [31], gastric [32] and prostate [33] carcinomas and 
hematologic malignancies such as lymphomas, T-ALLs 
and CLLs [34], where it is associated with EMT and 
cancer stem cells self-renewal and preservation [35, 36]. 
Also, NOTCH1 pathway signaling is hyperactive during 
K-Ras(+/LSLG12Vgeo);RERTn(ert/ert) mouse lung carcinogenesis 
and is required for tumor maintenance [37]. There is 
increasing evidence for an important link between the 
PI3K/AKT/mTOR pathway and NOTCH1 in sustaining 
the cancer stem cell niche [27]. In particular, NOTCH1 
decreases PTEN protein levels through Hes1, a NOTCH1 
transcriptional target, which binds PTEN promoter and 
represses its activity. Moreover, NOTCH1 increases 
Figure 8: Schematic representation of miR-494-3p-NOTCH1-PI3K-AKT signaling in lung cancer cells. 
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Interleukin-7 Receptor α and Insulin-like Growth Factor 
1 Receptor (IGF-1R) protein levels, which activate 
PI3K/Akt signaling. In lung adenocarcinoma, IGF-
1R overexpression and Akt activation by NOTCH1 
is stimulated by hypoxic microenvironment [38], and 
NOTCH1 targeting may provide a viable therapeutic 
approach for patients with K-Ras mutant lung 
adenocarcinoma [39]. 
In summary, we have identified miR-494-3p 
as a potentially critical theranostic marker of tumor 
progression in NSCLCs. These results may open concrete 
new prospects for targeting a NOTCH1-PI3K–AKT–
mTOR1 signaling axis in patients with lung cancer.
MATERIALS AND METHODS
Mouse samples collection
Lung hyperplasia (Hyp), adenoma (Ad), 
adenocarcinoma (AdCa) and non-neoplastic lung 
(4-OHT+N) tissues (at least 104 cells per sample) were 
obtained by laser-assisted microdissection (LMD; 
Leica Microsystems, Milan, Italy) from formalin-
fixed and paraffin embedded (FFPE) lungs of K-Ras(+/
LSLG12Vgeo);RERTn(ert/ert) mice at 2 (n = 2), 5 (n = 2) and 9 (n 
= 4) months following K-Rasv12 oncogene induction by 
4-OHT intraperitoneal injection (0.5 mg per dose, 3 
doses per week, for 2 weeks). Hyperplastic lung lesions 
were identified in animals after 2, 5 and 9 months from 
oncogene expression. Adenomas were present in mice 
after 5 and 9 months following 4-OHT administration. 
Adenocarcinomas were detected in animals after 9 
months from oncogene induction. Aged-matched normal 
lung tissues (N) were also purified from aged-matched 
littermates at 2, 5 and 9 months of age without K-Rasv12 
oncogene induction (Supplementary Table 10).
Lung tissue morphology was evaluated on 
haematoxylin and eosin (H&E) stained sections to 
confirm presence of lesions or of normal lung tissue. 
All experiments involving mice were approved by an 
Institutional Animal Care and Use Committee.
Lung cancer patients
A series of 113 non-small cell lung cancer (NSCLC) 
patients who underwent surgery for therapeutic purposes 
at Fondazione IRCCS Ca’ Granda-Ospedale Maggiore 
Policlinico Hospital (Milan, Italy) were enrolled for this 
study. The research was approved by the Fondazione 
IRCCS Ca’ Granda-Ospedale Maggiore Policlinico Ethical 
committee. All clinical investigation has been conducted 
according to the principles expressed in the Declaration 
of Helsinki and data were analyzed anonymously. For all 
patients clinico-pathological correlates were available. 
Disease-free survival status was available for 57 patients, 
whereas overall survival records were available for 
the entire cohort. Patients’ characteristics are detailed 
in Supplementary Table 11. Lung cancer tissues were 
available from all patients whereas non-neoplastic 
counterparts at a minimum distance from tumor of 5 cm 
were available for 57 patients. For all lung cancer samples, 
a pathologist (SB or SF) confirmed on histological sections 
that epithelial tumor cells represented at least 80% of the 
tissue.
Tumor bulk and periphery (invasive front) were 
isolated by laser-assisted microdissection from 16 cases 
of NSCLC.
Cell cultures
The human lung cancer cell line A549 was 
purchased from American Type Culture Collection 
(ATCC, Teddington, UK). Cells were cultured in RPMI 
supplemented with 10% FBS and 1 % of Penicillin 
and Streptomycin (all from Thermo Fisher Scientific, 
Waltham, MA, USA) and maintained at 37°C and 5% CO2. 
For miRNA transfection experiments, A549 cells were 
seeded at 2x106 cells/ml in 6-wells plates and transfected 
with miR-494-3p Mimic (100 nM, Sigma Aldrich, Milan, 
Italy), miR-494-3p Inhibitor (150 nM, Sigma Aldrich) or 
with a Mimic/Inhibitor control (50 nM, Sigma Aldrich) 
in the presence of 5 µl of Lipofectamine 2000 (Thermo 
Fisher Scientific) in 1ml of OptiMem Medium (Thermo 
Fisher Scientific). After transfection, cells were maintained 
in complete medium for 48 to 72 h, and processed for 
individual experiments.
Side population analysis
Side population (SP) analyses were performed as 
already described [17, 40]. Briefly, transfected A549 cells 
were resuspended at 1x106 cells/ml in pre-warmed DMEM 
supplemented with 2% FBS and 10mM HEPES (all from 
Thermo Fisher Scientific). Hoechst 33342 dye was added 
at the final concentration of 5 µg/ml in presence or absence 
of Verapamil (50 µM, Sigma Aldrich) and cells were 
incubated at 37°C for 2h with intermittent shaking. At the 
end of the incubation, cells were washed by centrifugation 
at 4°C with ice-cold HBSS (Thermo Fisher Scientific) and 
resuspended at the final concentration of 2x107 cells/ml 
with cold HBSS w/o Ca2+/Mg2+ supplemented with 2% 
FBS and 10mM HEPES. In order to exclude dead cells, 
propidium iodide (PI, Sigma Aldrich) was added at the 
final concentration of 5µg/ml. SP analyses and cell sorting 
were conducted on FACSAria II SORP (Becton Dickinson, 
San Josè, CA, USA) equipped with a FACSDiva software 
(version 7.0). The first FSC-H versus FSC-A dot plot was 
used to exclude doublet cells from the analysis. The gate 
on SFC-A and SSC-A in the second dot plot was used to 
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exclude debris. The third dot plot reporting SSC-A and PI 
fluorescence allowed the exclusion of dead cells from the 
analysis of SP without affecting the Hoechst 33342 profile. 
PI florescence was excited with a blue laser emitting at 
488 nm and collected at 620-640 nm. The final dot plot 
with the Hoechst blue and red fluorescence shown on a 
linear scale was used to identify the SP (Supplementary 
Figure 5). The Hoechst 33342 dye was excited with 
ultra violet laser emitting at 355 nm and its emission 
fluorescence was dual-wavelength analyzed (Hoechst 
blue, 425–475 nm; Hoechst red, 650–700 nm). The SP 
was the final population that disappeared in the samples 
treated with Verapamil (Supplementary Figure 5A, B) as 
described [17, 40]. 
Transcription factor array
A549 cells were reverse-transfected with Mimic/
Inhibitor control and miR-494-3p Mimic/Inhibitor (26 
nM) on a 96-wells plate pre-coated with reporter genes 
for 10 transcription factors (TF), as well as positive 
and negative controls (Cignal Finder Reporter array, 
Signal Transduction 10 Pathways, SaBiosciences Corp., 
Frederick, MD; Supplementary Table 9) as described 
[17]. Cells were harvested after 72 h and dual luciferase 
emission was assessed using a Dual-Glo Luciferase 
Assay (Promega Corporation, Madison, WI, USA) and a 
luminometer. Firefly luciferase emission was normalized 
on Renilla for each sample. Values of negative controls 
were used to set the threshold for TF activity. Relative 
pathway activation was calculated in miR-494-3p over 
expressing cells compared to control and a p-value < 0.05 
were set as cut-off for significant difference.
Migration assay
After 48h from miRNA Mimics transfection, a 
wound was created in the monolayer of A549 cells using 
a P200 micropipette tip. Cells were washed with PBS 
and incubated in complete medium for 24h at 37°C and 
5%CO2. To measure the wound closure, three random 
pictures were taken at 50x magnification when the scratch 
was performed (T0) and after 24h (T24). The migration 
distance was determined as reduction in the wound gap 
using NIH Image-J software, as already described [2].
Spheres formation
After 48h of transfection with miR-494-3p Mimic 
and control, A549 cells (5x103 cells/ml) were seeded in 
poly-HEMA (20mg/ml, Sigma Aldrich) coated 6-wells 
plates in serum-free DMEM medium supplemented with 
20 ng/ml human recombinant basic fibroblast growth 
factor (bFGF) and 20 ng/ml epidermal growth factor 
(EGF; all from Thermo Fisher Scientific). The medium 
was supplemented with fresh growth factors every 2 days 
until the cells started to grow and form floating tumor 
spheres. Tumor spheres were analyzed after 7 days. 
In vivo tumor growth and metastatic 
dissemination analyses
Fourteen male athymic nude-Foxn1nu mice (Harlan 
Laboratories Srl, Udine, Italy) at 6 weeks of age were 
injected subcutaneously into the lower flank with 5x105 
A549 cells transfected with a Mimic control (Ctrl) or a 
miR-494-3p Mimic in a total volume of 200 μl of sterile 
PBS (seven mice per condition). Tumor growth was 
monitored by caliper and animals were euthanized after 
18 days. Tumor volume (cm3) was calculated using the 
formula: Volume = (width)2 × length/2. Xenografts were 
formalin-fixed and paraffin embedded for histological 
examination. 
Twenty-six male athymic nude-Foxn1nu mice 
(Harlan Laboratories Srl) were injected intravenously into 
the lateral tail vein with 5x105 A549 cells transfected with 
a Mimic control (Ctrl)or a miR-494-3p Mimic in a total 
volume of 200 μl of sterile PBS (13 mice per condition). 
The onset of metastatic tumor foci was monitored using 
magnetic resonance image (MRI) at day 10 and day 17. At 
mice sacrifice (day 18), lungs and liver were collected and 
processed following standard histopathological procedures 
(FFPE). Metastatic foci to the lung were then analyzed 
using Leica IM 500 V5 software (Leica Microsystems) 
and their number and area were scored and recorded by 
AF, VV and SB.
All experiments involving animals were approved 
by an Institutional Animal Care and Use Committee 
(IACUC) at Nerviano Medical Sciences, in compliance 
with the Italian Ministry of Health.
MRI in vivo acquisition
MRI scans were acquired on anesthetized animals 
(isofluoran gas anaesthesia) using a Bruker Pharmascan 
instrument operating at 7.0 T magnetic field. Mice were 
positioned prone on the animal bed and inserted in the 
radiofrequency coil (38 mm i.d.) inside the magnet. After 
scout transverse imaging for correct positioning, spin echo 
(MSME) coronal images were acquired to cover the whole 
lungs. Acquisition parameters were as follows: TR/TE = 
600/12 ms; 4 averages, FOV = 4*4, slice thickness: 0.55 
mm, 22 slices. The acquisition was triggered to the animal 
respiratory cycle, in order to reduce thoracic movement 
artifacts. The whole in vivo examination lasted around 30 
minutes per animal.
All experiments involving animals were approved 
by an Institutional Animal Care and Use Committee 
(IACUC) at Nerviano Medical Sciences, in compliance 
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with the Italian Ministry of Health.
Genomic DNA extraction and bisulfite treatment
Genomic DNA was purified from patients’ frozen 
samples using DNeasy Blood and Tissue Kit following the 
manufacturer’s instructions (Qiagen, Hilden, Germany). 
DNA was quantified by Qubit 2.0 fluorimeter (Thermo 
Fisher Scientific) and bisulfite-modified using Epitect 
Bisulfite Kit (Qiagen), according with the manufacturer’s 
protocol. Bisulfite converted DNA was eluted in 20 μl and 
used for HRM analysis. 
Differential high resolution melting analysis
PCR amplification and HRM analysis were 
conducted using a Rotor-Gene 6000 (Corbett Research, 
Sydney, Australia) instrument. Primers were designed 
by Methyl Primer Express software (Thermo Fisher 
Scientific) in order to amplify a 340 bp product 
containing 16 CpG sites at the intergenic differentially 
methylated region (IG-DMR) of human DLK1-DIO3 
locus. The primer sequences were as follows: IG-Met4F: 
5’-GGGAATTGGGGTATTGTTTATA-3’ and IG-Met3R: 
5’-TAACCAATTACAATACCACAAAATTAC-3’. PCR 
amplification was carried out in a final volume of 25 μl 
containing: 1X FastStart SYBR Green Master (Roche, 
Indianapolis, IN, USA), 360 nM of each primer and 2 
ng of bisulfite treated DNA template. The thermal profile 
was 10 min at 95° C followed by 40 cycles including 30 
sec at 95° C, 30 sec at 59°C, 30 sec at 72° C. HRM was 
performed ramping from 69° C to 85° C and rising by 0.1° 
C every 2 sec.
The normalization of melting curves was performed 
for two normalization regions before and after the major 
fluorescence decrease using Rotor-Gene 6000 Series 
Software 1.7. The algorithm applied by the software 
permits the direct comparison of samples with different 
starting fluorescence levels. A differential profile was 
then evaluated for each sample by comparing the value 
of fluorescence at the melting point against the value of 
fluorescence of an unmethylated DNA control (Epitect 
PCR Control DNA Set - Qiagen) as described [41]. 
Quantification was calculated by interpolation on an 
external standard curve generated by serial dilutions of a 
control methylated DNA (100, 90, 75, 60, 50, 40, 25 and 
10 % - Epitect PCR Control DNA Set - Qiagen). DNA 
from 12 matched lung normal and cancer tissues and a 
normal blood samples were investigated. All samples were 
analyzed in triplicate.
Array-based comparative genome hybridization 
(a-CGH)
Genomic DNA was purified from 20 lung cancer 
samples and matched non-neoplastic counterparts using 
TRIzol Reagent (Thermo Fisher Scientific) following 
manufacturer’s instructions. A-CGH analysis was 
performed using a 60-mer oligonucleotide probes 
technology (SurePrint G3 Human CGH 8x60K, Agilent 
Technologies, Santa Clara, CA, USA) according to 
supplier’s information and as previously described 
[42]. Raw data were generated using Agilent Feature 
extraction and analysed by Cytogenomics 2.0.6.0. 
(Agilent Technologies). Copy number variations analysis 
was performed using ADAM2 algorithm. To improve the 
accuracy of the results the Diploid Peak Centralization 
algorithm was applied.
The aberration filter was set to detect a minimum 
number of 3 consecutive probes/region and the minimum 
absolute average Log Ratio (MAALR) was ± 0,25. A 
second analysis was run with a MAALR of ±0,15 and with 
a minimum number of 5 probes/region to detect low level 
mosaicism.
Copy number variations described in the Database 
of Genomic Variants (http://projects.tcag.ca/variation/) are 
not reported.
Statistical analysis
For miRNAs profiling, log2-transformed data 
from miRNAs arrays were imported in BRB-ArrayTools 
software (http://linus.nci.nih.gov/BRB- ArrayTools.html), 
quantile normalized and filtered to exclude miRNAs with 
low variability within samples pools (less than 20% of 
expression data with at least a 1.5 -fold change in either 
direction from gene’s median value). Four hundred and 
eighty-six miRNAs were available for further analyses. In 
order to identify miRNAs potentially deregulated during 
cancer progression, we performed a Class Comparison 
analysis between normal (N), non-neoplastic (4-OHT+N), 
hyperplastic (Hyp), adenomatous (ad) and adenocarcinoma 
(Adca) lesions. Results were considered significant if the 
p-value was less than 0.05 and the fold-change was at 
least 2. For scatterplots generation, a fold-change of 10 
was chose as cut-off for miRNA differential expression. 
For both overall and disease-free survival analyses, 
the Kaplan-Meier method was used. NSCLC patients were 
categorized into “high” or “low” expressor group if their 
miRNA level was above or below the miRNA median 
value, or if they upregulated more than 8 chromosome 
14q32 miRNAs (>8) or not (≤ 8 miRNAs). 
Differences in miRNAs expression levels between 
matched lung tumor and normal samples were analyzed 
by paired Student’s t test (Prism 4.0, GraphPad Inc, La 
Jolla, CA, USA). 
Oncotarget15www.impactjournals.com/oncotarget
Receiver operating characteristic (ROC) curve 
analysis was used to identify the best ABCG2 value able 
to discriminate between tumors with elevated expression 
of at least nine 14q32 miRNAs from cases with low 14q32 
miRNAs abundance using the Youden associated criterion 
(J index = 0.578, MedCalc Software, Ostend, Belgium) as 
described [43]. 
Correlation between miR-494-3p and pri-miR-494 
levels has been analyzed using the Spearman Rank 
Correlation. Differences in DNA methylation between 
tumor and normal tissues were analyzed by Mann-
Whitney U test. Correlation between pri-miR-494 and 
submicroscopic genomic alteration of DLK1-DIO3 
region was analyzed using Fisher’s exact test. Differences 
in gene expression among A549 cells transfected with a 
miR-494-3p Mimic or a control were analyzed by Mann-
Whitney U test. Correlation between miR-494-3p and 
pri-miR-494 levels has been analyzed using the Spearman 
Rank Correlation. Correlation between pri-miR-494 and 
submicroscopic genomic alteration of DLK1-DIO3 region 
was analyzed using Fisher’s exact test. All analyses were 
performed using Prism 4.0 software (GraphPad Inc)
Ingenuity Pathway system (Ingenuity Systems Inc., 
Redwood City, CA, USA) was used to infer on cellular 
networks with biological significance using as dataset the 
analyzed genes (Supplementary Table 8) in A549 cultures 
overexpressing the miR-494-3p or a control construct. 
For in vitro and in vivo experiments, differences 
among samples with miR-494-3p overexpression or 
control were analyzed using the unpaired Student’s t 
test or the Mann-Whitney U test as indicated (Prism 4.0, 
GraphPad Inc).
RNA purification and retrotranscription, miRNAs 
and genes expression analyses, immunoblotting and 
immunohistochemical procedures and Boyden Chamber 
Assay are detailed in the Supplementary Methods.
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